SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

A fair growth of 5.32% in the revenue at Rs. 2904.81 millions was reported in the March 2023 quarter as compared to Rs. 2758.19 millions during year-ago period.The Net Loss for the quarter ended March 2023 is Rs. -309.11 millions as compared to Net Loss of Rs. -631.86 millions of corresponding quarter ended March 2022Operating profit surged to 663.31 millions from the corresponding previous quarter of 557.14 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 2904.81 2758.19 5.32 11519.57 9880.90 16.58 11519.57 9880.90 16.58
Other Income 99.90 206.35 -51.59 332.82 424.97 -21.68 332.82 424.97 -21.68
PBIDT 663.31 557.14 19.06 2553.73 2362.02 8.12 2553.73 2362.02 8.12
Interest 218.23 234.95 -7.12 921.66 955.45 -3.54 921.66 955.45 -3.54
PBDT 178.60 322.19 -44.57 1365.59 1389.65 -1.73 1365.59 1389.65 -1.73
Depreciation 92.86 817.78 -88.64 573.62 1309.70 -56.20 573.62 1309.70 -56.20
PBT 85.74 -495.59 -117.30 791.97 79.95 890.58 791.97 79.95 890.58
TAX 394.85 136.27 189.76 367.26 137.05 167.98 367.26 137.05 167.98
Deferred Tax 233.62 -109.17 -314.00 233.62 -109.17 -314.00 233.62 -109.17 -314.00
PAT -309.11 -631.86 -51.08 424.71 -57.10 -843.80 424.71 -57.10 -843.80
Equity 590.87 590.87 0.00 590.87 590.87 0.00 590.87 590.87 0.00
PBIDTM(%) 22.83 20.20 13.05 22.17 23.90 -7.26 22.17 23.90 -7.26

Ind-Swift Lab. Share Price

132.10 0.10 (0.08%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×